Vestnik dermatologii i venerologiiVestnik dermatologii i venerologii0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov120810.25208/vdv1208Review ArticleCeftriaxone treatment of syphilisKatuninGeorgiy L.<p>dermatovenereologist</p>g.katunin@rambler.ruhttps://orcid.org/0000-0003-0599-6305PlakhovaXenia I.<p>MD, Dr. Sci. (Med.)</p>plahova_xenia@mail.ruhttps://orcid.org/0000-0003-4169-4128AbuduevNazirbek K.<p>MD, Dr. Sci. (Med.)</p>ankor@mail.ruhttps://orcid.org/0000-0002-6550-9348VasilievMichael M.<p>MD, Dr. Sci. (Med.)</p>ainfo@omxcourson.ruState Research Center of Dermatovenereology and Cosmetology2804202197223312001202105032021Copyright © 2021, Katunin G.L., Plakhova X.I., Abuduev N.K., Vasiliev M.M.2021<p>The article presents literature data on the use of antibacterial drugs for the treatment of patients with syphilis, where the main focus is on ceftriaxone. Based on the materials of national and foreign studies, data on the effectiveness of ceftriaxone in the treatment of patients with various forms of syphilis have been analyzed, and information characterizing the pharmacological and pharmacokinetic features of ceftriaxone has been presented. Based on the scientific and clinical experience accumulated over previous years, both in Russia and abroad, some results of the use of ceftriaxone in the treatment of syphilis have been summed up. To search for the necessary literature, the PubMed, MedLine, Web of Science and RSCI databases were used.</p>syphilistreatmentceftriaxonereviewсифилислечениецефтриаксонобзор[Mahoney JF, Arnold RC, Harris A. Penicillin treatment of early syphilis-A preliminary report. Am J Public Health Nations Health. 1943;33(12):1387–1391. doi:10.2105/ajph.33.12.1387][Федеральные клинические рекомендации. Дерматовенерология. 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и дополн. М.: Деловой экспресс, 2016. С. 768. [Federal'nye klinicheskie rekomendacii. Dermatovenerologiya. 2015: Bolezni kozhi. Infekcii, peredavaemye polovym putem. 5-e izd., pererabotannye i dopolnennye. Moscow: Delovoj ekspress, 2016. P. 76 (In Russ.)]][Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;5;64(RR-03):1–137. Erratum in: MMWR Recomm Rep. 2015;28;64(33):924.][Janvier M, Hegyi V, Dupin N, et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014;28(12):1581–1593. doi: 10.1111/jdv.12734][Kingston M, French P, Higgins S, et al. UK National Guidelines of the Management of Syphilis 2015. Int J STD AIDS. 2016;27(6):421–446. doi: 10.1177/0956462415624059][Deka RK, Machius M, Norgard MV, Tomchick DRJ. Crystal structure of the 47-kDa lipoprotein of Treponema pallidum reveals a novel penicillin-binding protein. Biol Chem. 2002;277(44):41857–41864. doi: 10.1074/jbc.M207402200][Cha JY, Ishiwata A, Mobashery SJ. A novel beta-lactamase activity from a penicillin-binding protein of Treponema pallidum and why syphilis is still treatable with penicillin. Biol Chem. 2004;279(15):14917–14921. doi: 10.1074/jbc.M400666200][Stamm LV. Global challenge of antibiotic-resistant Treponema pallidum. Antimicrob Agents Chemother. 2010;54(2):583–589. doi: 10.1128/AAC.01095-09][Montgomery CH, Knox JM, Sciple GW, Vander Stoep EM. Erythromycin in treatment of early syphilis. Arch Intern Med. 1961;107:732–735. doi: 10.1001/archinte.1961.03620050098010][Лебедева Г.В. Лечение эритромицином больных сифилисом. Вестник дерматологии венерологии. 1965;10:45–48. [Lebedeva GV. Lechenie eritromicinom bol'nyh sifilisom. Vestnik dermatologii I venerologii. 1965;10:45–48 (In Russ.)]][Verdon MS, Handsfield HH, Johnson RB. Pilot study of azithromycin for treatment of primary and secondary syphilis. Clin Infect Dis. 1994;19:486–488. doi: 10.1093/clinids/19.3.486][Борисенко К.К., Лосева O.K., Бондаренко Т.Ф. Некоторые отдаленные результаты лечения больных ранними формами сифилиса сумамедом. Вестник дерматологии и венерологии. 1997;2:42–44. [Borisenko KK, Loseva OK, Bondarenko TF. Nekotorye otdalennye rezul'taty lecheniya bol'nyh rannimi formami sifilisa sumamedom. Vestnik dermatologii i venerologii. 1997;2:42–44 (In Russ.)]][Hook EW, Martin DH, Stephens J, et al. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis. 2002;29(8):486–490. doi: 10.1097/00007435-200208000-00010][Marra CM, Colina AP, Godornes C, et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis. 2006;194:1771–1773. doi: 10.1086/509512][Matejkova P, Flasarova M, Zakoucka H, et al. Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in 23S rRNA gene of Treponema pallidum subsp. pallidum. J Med Microbiol. 2009;58:832–836. doi: 10.1099/jmm.0.007542-0][Beale MA, Marks M, Sahi SK, et al. Genomic epidemiology of syphilis reveals independent emergence of macrolide resistance across multiple circulating lineages. Nat Commun. 2019;22;10(1):3255. doi: 10.1038/s41467-019-11216-7][Hartmann JF, Lescoeur B, Mercier JC, et al. Neonatal syphilis despite erythromycin treatment of the Mother. Presse Médicale. 1984;13(35):2133–2135.][Zhou P, Qian Y, Xu J, Gu Z, et al. Occurrence of congenital syphilis after maternal treatment with azithromycin during pregnancy. Sex Transm Dis. 2007;34(7):472–474. doi: 10.1097/01.olq.0000246314.35047.9][Heikkinen T, Laine K, Neuvonen PJ, Ekblad U. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG. 2000;107(6):770–775. doi: 10.1111/j.1471-0528.2000.tb13339.x][Onoda Y. Therapeutic effect of oral doxycycline on syphilis. Br J Vener Dis. 1979;55(2):110–115. doi: 10.1136/sti.55.2.110][Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;15;42(6):e45–9. doi: 10.1086/500406][Li J, Zheng HY. Early syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. J Infect Dev Ctries. 2014;13;8(2):228–232. doi: 10.3855/jidc.3013][Кубанова А.А, Кубанов А.А., Фриго Н.В. и др. Первый опыт молекулярного типирования и определения антибиотикорезистентности штаммов возбудителя сифилиса Treponema pallidum в Российской Федерации. Вестник дерматологии венерологии. 2013;3:34–46. [Kubanova AA, Kubanov AA, Frigo NV, et al. First experience of molecular typing and determining the antibiotic resistance of syphilis pathogen Treponema pallidum in the Russian Federation. Vestnik dermatologii i venerologii. 2013;3:34–46 (In Russ.)]][Gonzalez-Ochoa A, Moreno JB. The treatment of early syphilis with cephaloridine. Postgrad Med J. 1967;43:Suppl 43:134–135.][Glicksman JM, Short DH, Knox JM. Parenteral cephaloridine treatment of patients with early syphilis. Arch Intern Med. 1968; 121(4):342–344.][Nicolis G, Loucopoulos A. Cephalothin in the treatment of syphilis. Br J Vener Dis. 1974;50(4):270–271. doi: 10.1136/sti.50.4.270][Cleeland R, Squires E. Antimicrobial activity of ceftriaxone: a review. Am J Med. 1984;19;77(4C):3–11.][Горчакова Н.А. Клиническая фармакология антибиотиков группы цефалоспоринов. Therapia. 2008;5(26):42–48. [Gorchakova NA. Klinicheskaja farmakologija antibiotikov gruppy cefalosporinov. Therapia. 2008;5(26):42–48 (In Russ.)]][Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet. 1989;17(4):223–235. doi: 10.2165/00003088-198917040-00002][Nau R, Prange HW, Muth P, et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother. 1993;37(7):1518–1524. doi: 10.1128/aac.37.7.1518][Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet. 2000;39(5):335–343. doi: 10.2165/00003088-200039050-00003][Matsuda S, Suzuki M, Shimizu T, et al. Pharmacokinetic and clinical evaluations of ceftriaxone in perinatal infections in obstetrics and gynecology. Jpn J Antibiot. 1988;41(9):1251–1260.][Bourget P, Fernandez H, Quinquis V, Delouis C. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. Antimicrob Agents Chemother 1993;37:54–59. doi: 10.1128/aac.37.1.54][Johnson RC, Bey RF, Wolgamot SJ. Comparison of the activities of ceftriaxone and penicillin G against experimentally induced syphilis in rabbits. Antimicrob Agents Chemother. 1982;21(6):984–989. doi: 10.1128/aac.21.6.984][Korting HC, Walther D, Teithmuller U. et al. Comparative in vitro susceptibility of Treponema pallidum to cetrizoxime, ceftriaxone and penicillin G. Chemotherapy 1986;32(4):352–355. doi: 10.1159/000238434][Korting HC, Walther D, Riethmüller U, Meurer M. Ceftriaxone given repeatedly cures manifest syphilis in the rabbit. Chemotherapy. 1987;33(5):376–380. doi: 10.1159/000238523][Moorthy TT, Lee CT, Lim KB, Tan T. Ceftriaxone for treatment of primary syphilis in men: a preliminary study. Sex Transm Dis. 1987;14(2):116–118. doi: 10.1097/00007435-198704000-00013][Katsambas A, Adoniou C, Katsarou A, Kerkidou A, Stratigos J. Comparative study of ceftriaxone and benzathine penicillin G in the treatment of primary and secondary syphilis. Chemioterapia. 1987;6(2 Suppl):549–550.][Hook EW, Roddy RE, Handsfield HH. Ceftriaxone therapy for incubating and early syphilis. J Infect Dis. 1988;158(4):881–884.doi: 10.1093/infdis/158.4.881][Schofer H, Vogt HJ, Milbradt R. Ceftriaxone for the treatment of primary and secondary syphilis. Chemotherapy. 1989;35:140–145. doi: 10.1159/000238661][Hook EW, Baker-Zander SA, Moskovitz BL, et al. Ceftriaxone therapy for asymptomatic neurosyphilis. Case report and Western blot analysis of serum and cerebrospinal fluid IgG response to therapy. Sex Transm Dis. 1986;13(3 Suppl):185–188.][Dowell ME, Ross PG, Musher DM, et al. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am J Med. 1992;93(5):481–488. doi: 10.1016/0002-9343(92)90574-u][Marra CM, Slatter V, Tartaglione TA, et al. Evaluation of aqueous penicillin G and ceftriaxone for experimental neurosyphilis. J Infect Dis. 1992;165(2):396–397. doi: 10.1093/infdis/165.2.396][Cnossen WM, Niekus H, Nielsen O, et al. Ceftriaxone treatment of penicillin resistant neurosyphilis in alcoholic patients. J Neurol Neurosurg Psychiat. 1995;59:194–195. doi: 10.1136/jnnp.59.2.194][Gentile JH, Viviani C, Sparo MD, Arduino RC. Syphilitic meningomyelitis treated with ceftriaxone: case report. Clin Infect Dis. 1998;26(2):528. doi: 10.1086/517112][World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: WHO, 2001.][Augenbraun M, Workowski K. Ceftriaxone therapy for syphilis: report from the emerging infections network. Clin Infect Dis. 1999; 29:1337–1338. doi: 10.1086/313489][Привалова Н.К., Тихонова Л.И. Заболеваемость сифилисом в Российской Федерации: анализ тенденций и прогноз развития эпидемической ситуации. Инфекции, передаваемые половым путем 2000;5:35–40. [Privalova NK, Tihonova LI. Zabolevaemost' sifilisom v Rossijskoj Federacii: analiz tendencij i prognoz razvitiya epidemicheskoj situacii. Infekcii peredavaemye polovym putem 2000;5:35–40 (In Russ.)]][«О мерах по предупреждению распространения инфекций, передаваемых половым путем»: Приказ Минздрава РФ № 291 от 30.07.2001. М.: МЗ РФ, 2001. [“O merah po preduprezhdeniyu rasprostraneniya infekcij, peredavaemyh polovym putem”: Prikaz Minzdrava RF № 291 ot 30.07.2001. Moscow: MZ RF, 2001 (In Russ.)]][Аковбян В.А., Кубанов A.A., Дмитриев Г.А. Цефтриаксон (роцефин) при лечении больных сифилисом. Вестник дерматологии и венерологии. 1997;3:27–29. [Akovbyan VA, Kubanov AA, Dmitriev GA. Ceftriakson (rocefin) pri lechenii bol'nyh sifilisom. Vestnik dermatologii i venerologii. 1997;3:27–29 (In Russ.)] doi: 10.25208/0042-4609-2014-90-1-45-52][Дмитриев Г.А., Аковбян В.А., Кубанов A.A. и др. Ультраструктурные изменения Treponema pallidum в процессе лечения больных сифилисом цефтриаксоном (роцефином). Вестник дерматологии и венеролологии. 1997;5:11–14. [Dmitriev GA, Akovbyan VA, Kubanov AA, et al. Ul'trastrukturnye izmeneniya Treponema pallidum v processe lecheniya bol'nyh sifilisom ceftriaksonom (rocefinom). Vestnik dermatologii i venerologii. 1997;5:11-14 (In Russ.)] doi: 10.25208/0042-4609-2014-90-1-45-52][Методические указания № 98/273 «Лечение и профилактика сифилиса». М.: Минздрав России, 1999. 20 с. [Metodicheskie ukazaniya № 98/273 “Lechenie i profilaktika sifilisa”. Moscow: Minzdrav Rossii, 1999. 20 s. (In Russ.)]][Давыдова Т.В., Кулагин В.И., Чистякова Т.В. и др. Антиоксидантный статус у больных серорезистентным сифилисом. Российский журнал кожных и венерических болезней. 2002;6:51–55. [Davydova TV, Kulagin VI, CHistyakova TV, et al. Antioksidantnyj status u bol'nyh serorezistentnym sifilisom. Rossijskij zhurnal kozhnyh i venericheskih boleznej. 2002;6:51–55 (In Russ.)]][Кубанова А.А., Доля О.В. Опыт применения цефтриаксона (роцефин) при сифилисе у беременных и новорожденных, а также у детей с серорезистентностью. Вестник дерматологии и венерологии. 2001;2:70–75. [Kubanova AA, Dolya OV. Opyt primeneniya ceftriaksona (rocefin) pri sifilise u beremennyh i novorozhdennyh, a takzhe u detej s serorezistentnost'yu. Vestnik dermatologii i venerologii. 2001;2:70–75 (In Russ.)]][Александрова С.Г. Фармакокинетическое обоснование профилактики врожденного сифилиса цефтриаксоном. Антибиотики и химиотерапия. 2004;49(6):15–19. [Aleksandrova SG. Farmakokineticheskoe obosnovanie profilaktiki vrozhdyonnogo sifilisa ceftriaksonom. Antibiotiki i himioterapiya. 2004;49(6):15–19 (In Russ.)]][Ющенко О.М., Лосева О.К., Боровик В.З. и др. Ближайшие и отдаленные результаты лечения цефтриаксоном больных вторичным и ранним скрытым сифилисом. Вестник дерматологии и венерологии. 2003;6:55–58. [YUshchenko OM, Loseva OK, Borovik VZ, et al. Blizhajshie i otdalennye rezul'taty lecheniya ceftriaksonom bol'nyh vtorichnym i rannim skrytym sifilisom. Vestnik dermatologii i venerologii. 2003;6:55–58 (In Russ.)]][Ющенко О.М., Кабанова И.А., Лосева О.К. и др. Фармакокинетические характеристики и эффективность лечения цефтриаксоном больных вторичным и ранним скрытым сифилисом. Consilium medicum. Урогенитальные инфекции. 2003;5(3):82–84. [YUshchenko OM, Kabanova IA, Loseva OK, et al. Farmakokineticheskie harakteristiki i effektivnost' lecheniya ceftriaksonom bol'nyh vtorichnym i rannim skrytym sifilisom. Consilium medicum. Urogenital'nye infekcii. 2003;5(3):82–84 (In Russ.)]][Кубанова А.А. Дерматовенерология 2010. Клинические рекомендации (Российское общество дерматовенерологов). 4 изд. М.: ДЭКС-ПРЕСС, 2010. 347–386. [Kubanova AA. Dermatovenerologiya 2010. Klinicheskie rekomendacii (Rossijskoe obshchestvo dermatovenerologov). 4 izd. Moscow: DEKS-PRESS, 2010. 347–386 (In Russ.)]][Наволоцкая Т.И., Лосева О.К., Фриго Н.В. и др. Содержание прокаин-пенициллина и цефтриаксона в сыворотке крови, биологических жидкостях и тканях при лечении больных ранними формами сифилиса. Вестник последипломного медицинского образования. 2007;1:43–44. [Navolockaya TI, Loseva OK, Frigo NV, et al. Soderzhanie prokain-penicillina i ceftriaksona v syvorotke krovi, biologicheskih zhidkostyah i tkanyah pri lechenii bol'nyh rannimi formami sifilisa. Vestnik poslediplomnogo medicinskogo. obrazovaniya. 2007;1:43–44 (In Russ.)]][Лосева O.K., Ющенко О.М., Александрова С.Г. Исследование содержания цефтриаксона в жидкостях и тканях у больных сифилисом. Consilium medicum. Дерматология. 2008;1:67–70. [Loseva OK, YUshchenko OM, Aleksandrova SG. Issledovanie soderzhaniya ceftriaksona v zhidkostyah i tkanyah u bol'nyh sifilisom. Consilium medicum. Dermatologiya. 2008;1:67–70 (In Russ.)]][Корепанова М.В., Коробейникова Э.А., Крюкова О.И. Клиническая эффективность цефтриаксона в терапии ранних форм сифилиса. Клиническая дерматология и венерология. 2011;1:55–58. [Korepanova MV, Korobejnikova EA, Kryukova OI. Klinicheskaya effektivnost' ceftriaksona v terapii rannih form sifilisa. Klinicheskaya dermatologiya i venerologiya. 2011;1:55–58 (In Russ.)]][Заторская Н.Ф. Опыт применения цефтриаксона в лечении раннего врожденного сифилиса. Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2011;3:22–26. [Zatorskaya NF. Opyt primeneniya ceftriaksona v lechenii rannego vrozhdennogo sifilisa. Sovremennye problemy dermatovenerologii, immunologii i vrachebnoj kosmetologii. 2011;3:22–26 (In Russ.)]][Катунин Г.Л., Рубцов А.Б. Анализ отдаленных результатов лечения больных сифилисом с сохраняющимися положительными показателями нетрепонемных серологических тестов препаратом цефтриаксон. Вестник дерматологии и венерологии. 2014;1:46–52. [Katunin GL, Rubcov AB. Analysis of the long-term outcome of treatment of syphilitic patients with positive non-treponemal serology tests with the use of ceftriaxone. Vestnik Dermatologii i Venerologii. 2014;1:46–52 (In Russ.)]][Стрибук П.В., Лосева О.К., Юдакова В.М. Сравнительная эффективность лечения позднего нейросифилиса пенициллином и цефтриаксоном. Клиническая дерматология и венерология. 2016;15(1):18–22. [Stribuk PV, Loseva OK, YUdakova VM. Sravnitel'naya effektivnost' lecheniya pozdnego nejrosifilisa penicillinom i ceftriaksonom. Klinicheskaya dermatologiya i venerologiya. 2016;15(1):18–22 (In Russ.)] doi: 10.17116/klinderma201615118-22][Psomas KC, Brun M, Causse A, et al. Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis. Med Mal Infect. 2012;42(1):15–19. doi: 10.1016/j.medmal.2011.10.003][GE Hua, Wang Yu. Efficacy of ceftriaxone in treatment of serum recurrent syphilis cases. China tropical medicine. 2014;14(10):1284–1285.][Liu HY, Han Y, Chen XS, et al. Comparison of efficacy of treatments for early syphilis: A systematic review and network meta-analysis of randomized controlled trials and observational studies. PLoS One. 2017;28;12(6):e0180001. doi: 10.1371/journal.pone.0180001][Liang Z, Chen YP, Yang CS, Guo W, Jiang XX, Xu XF, Feng SX, Liu YQ, Jiang G. Meta-analysis of ceftriaxone compared with penicillin for the treatment of syphilis. Int J Antimicrob Agents. 2016;47(1):6–11. doi: 10.1016/j.ijantimicag.2015.10.020][Wendel GD Jr, Sheffield JS, Hollier LM, et al. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis. 2002;15;35(Suppl 2):S200-9. doi: 10.1086/342108][Zhou P, Gu Z, Xu J, et al. A study evaluating ceftriaxoneas a treatment agent for primary and secondary syphilis in pregnancy. Sexually Transmitted Diseases. 2005;32(8):495–498. doi: 10.1097/01.olq.0000170443.70739.cd][Roberts CP, Raich A, Stafylis C, Klausner JD. Alternative treatments for syphilis during pregnancy. Sex Transm Dis. 2019; 46(10):637–640. doi: 10.1097/OLQ.0000000000001050][Gentile JH, Viviani C, Sparo MD, Arduino RC. Syphilitic meningomyelitis treated with ceftriaxone: case report. Clin Infect Dis. 1998;26(2):528. doi: 10.1086/517112][Shann S., Wilson J. Treatment of neurosyphilis with ceftriaxone. Sex Transm Infect. 2003;79:415–416. doi: 10.1136/sti.79.5.415][Лукьянов А.М., Алексеев Н.А. Концентрация цефтриаксона в зависимости от различных режимов дозирования в сыворотке крови и гомогенате головного мозга в эксперименте, сыворотке крови и ликворе больных сифилисом с поражением структур нервной системы. Медицинская панорама. 2007;12:38–42. [Luk'yanov AM, Alekseev NA. Koncentraciya ceftriaksona v zavisimosti ot razlichnyh rezhimov dozirovaniya v syvorotke krovi i gomogenate golovnogo mozga v eksperimente, syvorotke krovi i likvore bol'nyh sifilisom s porazheniem struktur nervnoj sistemy. Medicinskaya panorama. 2007;12:38–42 (In Russ.)]][Güler E, Leyhe T. A late form of neurosyphilis manifesting with psychotic symptoms in old age and good response to ceftriaxone therapy. Int Psychogeriatr. 2011;23(4):666–669. doi: 10.1017/S104161021000181X][Ahmad Alam, Mohd Ashraf Alam, Khan HS, Rahman SZ. A vintage case with a novel treatment for neurosyphilis: A case report. Journal of pharmacovigilance and drug safety. 2019;16:10–12. doi: 10.21276/jpds.2019.16.01.05][Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2000;30(3):540–544. doi: 10.1086/313725][Smith NH, Musher DM, Huang DB, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. Int J STD AIDS. 2004;15(5):328–332. doi: 10.1177/095646240401500511][Pubben PGA, Soydemir S. Treatment of neurosyphilis in HIV-infected patients. A systematic review. Erasmus Journal of Medicine. 2011;1(2):27–30.][Spornraft-Ragaller P, Abraham S, Lueck C, Meurer M. Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone. Eur J Med Res. 2011;16(2):47–51. doi: 10.1186/2047-783x-16-2-47][Si WK, Suh KH, Lee MH, et al. Treatment of neurosyphilis with ceftriaxone in a patient infected with human immunodeficiency virus. Infect Chemother. 2011;43(3):262–265. doi:10.3947/IC.2011.43.3.262][Chen TC, Wang JH, Tsai TC. Repeated episodes of acute stroke as manifestation of neurosyphilis in a well-controlled human immunodeficiency virus-infected patient-Successful treatment with ceftriaxone. J Formos Med Assoc. 2017;116(9):725–726. doi: 10.1016/j.jfma.2017.01.007][Красносельских Т.В., Соколовский Е.В. Современные стандарты терапии сифилиса: сравнение российских и зарубежных клинических рекомендаций (сообщение II). Вестник дерматологии и венерологии. 2015;2:23–40. [Krasnosel'skih TV, Sokolovskiy EV. Current standards for syphilis treatment: comparing the russian and foreign guidelines (part II). Vestnik dermatologii i venerologii. 2015;2:23–40 (In Russ.)]][Lambert PA, Conway BR. Comparison of the pharmaceutical quality of generic ceftriaxone and rocefin preparations. Clinical microbiology and antimicrobial chemotherapy. 2004;6 (3):260–272.][Antunez C, Blanca Lopez M, Torres MJ. Immediate allergic reactions to cephalosporins evaluation of cros reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol. 2006;117(2):404–410. doi: 10.1016/j.jaci.2005.10.032]